Currently, out of the existing stock ratings of Laura Chico - 110 which are a Buy (67.07%), 52 which are a Hold (31.71%), 2 which are a Sell (1.22%)

Laura Chico

Work Performance Price Targets & Ratings Chart

Analyst Laura Chico works at WEDBUSH and is covering the Healthcare sector with 346 price targets and ratings displayed on 29 stocks. Previously, Laura Chico worked at RAYMOND JAMES.

Laura Chico's average stock forecast success ratio is 44.29% with an average time for price targets to be met of 143.38 days.

Most recent stock forecast was given on ARDX, Ardelyx at 13-Sep-2023.

Wall Street Analyst Laura Chico

Analyst best performing recommendations are on VERA.
The best stock recommendation documented was for APLS (APELLIS PHARMACEUTICALS) at 8/7/2023. The price target of $29 was fulfilled within 4 days with a profit of $5.35 (22.62%) receiving and performance score of 56.55.

Average potential price target upside

ACER Acer Therapeutics ALXN APLS Apellis Pharmaceuticals APTX Aptinyx ARDX Ardelyx BHVN Biohaven Pharmaceutical Holding Company Ltd BIIB Biogen DNLI Denali Therapeutics KRTX Karuna Therapeutics NBIX Neurocrine Biosciences PRAX Praxis Precision Medicines RARE Ultragenyx Pharmaceutical RTRX SAGE Sage Therapeutics TSHA Taysha Gene Therapies TVTX Travere Therapeutics VIE XENE Xenon Pharmaceuticals PRVL VYGR Voyager Therapeutics DSGN IMPL VERA STOK Stoke Therapeutics DOVA MLND PEPG VIGL VRTX Vertex Pharmaceuticals

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score



$7.19 (887.65%)


1 years 6 months 21 days ago

0/2 (0%)

$6.2 (271.90%)



$47.19 (5825.93%)


4 years 3 months 18 days ago

0/4 (0%)

$23.5 (118.58%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Laura Chico is most bullish on?

Potential upside of $21.54 has been obtained for NBIX (NEUROCRINE BIOSCIENCES)

Which stock is Laura Chico is most reserved on?

Potential downside of -$9.84 has been obtained for APLS (APELLIS PHARMACEUTICALS)

What Year was the first public recommendation made by Laura Chico?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart